Both Casgevy and Lyfgenia are highlighted in a recent Clarivate report among 13 potential “blockbuster and gamechanger” drugs to watch in 2024. Vertex's gene-editing therapy for sickle cell ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia. The former is notably the first FDA ...

President Trump signed an executive order on the day of his inauguration that created doubts about the future of a program ...

The two new therapies—Vertex Pharmaceuticals’ Casgevy and BlueBird Bio’s Lyfgenia—offer the 100,000 Americans and nearly 8 million people globally who suffer from sickle cell potential ...

Discover the latest addition to Children's Hospital Los Angeles' 10 cell and gene therapy treatments, including Casgevy for sickle cell disease ...

Opinions expressed by Forbes Contributors are their own. Joshua Cohen is a Boston-based writer who covers health policy. The Biden Administration announced this week that the manufacturers of ...

“Building on the success of CASGEVY’s launch, we continue to broaden our portfolio across oncology, autoimmune and cardiometabolic indications. 2025 promises to be a milestone-rich ...

Casgevy, developed with Vertex Pharmaceuticals ... Furthermore, Bluebird's Lyfgenia, which treats SCD, costs $3.1 million in the U.S. -- and comes with a warning for blood cancer.

Casgevy, a once-and-done treatment for sickle ... Bluebird bio's gene therapies Zynteglo and Lyfgenia were recently approved to treat beta-thalassemia and sickle cell disease, respectively.

Though the stock soared at the onset of 2024, thanks to the FDA approval of its one-shot gene therapy Casgevy for two blood disorders, much of these gains have pared mainly due to the waning ...